Articles tagged with “cancer-immunotherapy”

Trispecific Antibody HH160: BeOne and Huahui Licensing Deal

Analyze the BeOne-Huahui licensing agreement for the HH160 PD-1/CTLA-4/VEGF trispecific antibody. Review recent China biotech cross-border licensing trends.

40 min read

4/25/2026

trispecific antibodies china biotech licensing hh160 beone medicines huahui health cancer immunotherapy cross-border licensing immuno-oncology